Top Analyst Upgrades and Downgrades: Berkshire Hathaway, CarMax, Noble, Phillips 66, Portola Pharma, Qualcomm and More

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Top Analyst Upgrades and Downgrades: Berkshire Hathaway, CarMax, Noble, Phillips 66, Portola Pharma, Qualcomm and More

© courtesy of Jon Ogg

Stocks were indicated higher on Monday morning after a three-day Easter weekend, but many European markets were closed for the day. Now that stocks have risen but broken a five-week streak of gains, many investors are wondering if they need to start buying the dips or selling the rallies.

24/7 Wall St. reviews dozens of analyst research reports each morning of the week. The goal is to find new investing and trading ideas for our readers. Some of the daily analyst reports cover stocks to buy, and others cover stocks to sell or avoid.

These are top analyst upgrades, downgrades and initiations seen on Monday morning:

Berkshire Hathaway Inc. (NYSE: BRK-A) was started as Buy and was assigned a $244,500 price target (versus a $210,530 prior close) at UBS. Berkshire Hathaway has very few official analyst calls on it, and the 52-week trading range is $186,900 to $223,011.

CarMax Inc. (NYSE: KMX) was downgraded to Neutral from Buy at Sterne Agee CRT. The stock closed most recently at $48.83 and has a consensus analyst target price of $62.59 and a 52-week range of $41.25 to $75.40.
[recirclink id=322242]
Noble Corp. PLC (NYSE: NE) was reiterated and Buy and the price target was raised to $17 from $11 at Argus. The firm noted that commodity and oil prices have stabilized and started to recover, and that it sees more clarity on 2017 when the company reports first-quarter results. The stock closed at $10.43. The consensus price target is $9.63, and the 52-week range is$6.66 to $18.58.

Phillips 66 (NYSE: PSX) was started as Market Perform with a $92 price target (versus an $88.06 close) at Cowen. The consensus price target is $91.83, and the 52-week range is $69.79 to $94.12.

Portola Pharmaceuticals Inc. (NASDAQ: PTLA) was downgraded to Neutral from Buy and the price target was cut to $30 from $65 at Goldman Sachs. Credit Suisse kept an Outperform rating, but it lowered its target price to $34 from $47. Shares closed down 29.2% at $20.27 on Thursday, on 14 times normal volume after bad news on its blood clot trial results.

Qualcomm Inc. (NASDAQ: QCOM) was downgraded to Equal Weight from Overweight and the price target was cut to $50 from $55 (versus a $50.86 close) at Barclays. The consensus price target is $56.93. The 52-week range is $42.24 to $71.90.

You can follow @Jonogg to get the daily analyst calls and market reports directly on your Twitter feed.

Other key analyst upgrades and downgrades seen on Monday were in the following:

Agnico-Eagle Mines Ltd. (NYSE: AEM) was downgraded to Neutral from Buy at UBS.

Atwood Oceanics Inc. (NYSE: ATW) was downgraded to Underweight from Equal Weight and the price target was cut to $6 from $7 (versus an $8.43 close) at Barclays.

BB&T Corp. (NYSE: BBT) was downgraded to Underweight from Neutral with a $35 price target (versus a $33.69 close) at Piper Jaffray.

CF Industries Holdings Inc. (NYSE: CF) was downgraded to Neutral from Overweight and the price target was cut to $34 from $40 (versus a $31.94 close) at Piper Jaffray.

CIT Group Inc. (NYSE: CIT) was downgraded to Neutral from Buy and the price target was cut to $37 from $40 (versus a $33.46 close) at Sterne Agee CRT.

Corcept Therapeutics Inc. (NASDAQ: CORT) was reiterated as Buy with a $8.00 fair value estimate (versus a $4.29 close) at Janney Montgomery Scott. The call is ahead of important data expected at ASCO from a rare profitable small biotech, with expectations for broad utility of selective glucocorticoid receptor inhibition.

Dollar General Corp. (NYSE: DG) was reiterated as Buy and the price target was raised to $97 from $96 at Jefferies.
[recirclink id=322720]
ENSCO International PLC (NYSE: ESV) was downgraded to Negative from Neutral with an $8 price target (versus a $10.60 close) at Susquehanna.

Finish Line Inc. (NASDAQ: FINL) was reiterated as Buy and the price target was raised to $24 from $22 at Jefferies.

Goldcorp Inc. (NYSE: GG) was downgraded to Neutral from Buy at UBS.

H.B. Fuller Co. (NYSE: FUL) was raised to Overweight from Neutral and the price target was raised to $46 from $37 at JPMorgan.

KBR Inc. (NYSE: KBR) was raised to Neutral from Sell at Goldman Sachs.

Performance Sports Group Ltd. (NYSE: PSG) was downgraded to Underperform from Neutral at Bank of America Merrill Lynch.

SPX Corp. (NYSE: SPXC) was started as Outperform and the price target was put at $17 at Credit Suisse.

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618